Rui Kang Pharmaceutical Group Investments Limited provided consolidated earnings guidance for the year ended December 31, 2016. The board of directors of the company announced that based on the latest available information including the unaudited consolidated management accounts of the Group for the eleven months ended November 30, 2016 and the securities statements of the Group as at December 31, 2016, the Group is expected to record a significant loss for the year ended December 31, 2016 for its continuing operations as compared with that of approximately HKD 59.7 million for the corresponding period in 2015. The aforesaid loss was mainly attributable to a significant net loss of approximately HKD 25.7 million on financial assets at fair value through profit or loss during the 2016 year (as opposed to a net loss of approximately HKD 9.1 million for the corresponding period in 2015); the recognition of an impairment loss on trade receivables of approximately HKD 4.9 million during the 2016 Year (as opposed to approximately HKD 0.2 million for the corresponding period in 2015) as certain trade debts had been long overdue and the recovery of which were considered as remote; impairment of available-for-sale financial assets of approximately HKD 3.2 million during the 2016 Year (as opposed to nil for the corresponding period in 2015); and the write-off of certain property, plant and equipment of approximately HKD 5.9 million during the 2016 Year (as opposed to approximately HKD 7.5 million for the corresponding period in 2015).